Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management

References

• Cao Y, DePinho RA, Ernst M, Vousden K, Cancer research: past, present and future. Nat Rev Cancer 2011; 11:749-754; PMID:21918542; http://dx.doi.org/10.1038/nrc3138
   PubMed Web of Science ®Google Scholar
• Anderson AR. A hybrid mathematical model of solid tumour invasion: the importance of cell adhesion. Math Med Biol 2005; 22:163-186; http://dx.doi.org/10.1093/imammb/dqi005
   PubMed Web of Science ®Google Scholar
• Umer B, Good D, Anne J, Duan W, Wei MQ. Clostridial spores for cancer therapy: targeting solid tumour microenvironment. J Toxicology 20122012:862764
   PubMedGoogle Scholar
• Hodge JW, Ardiani A, Farsaci B, Kwilas AR, Gameiro SR. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012; 39:323-339; PMID:22595055; http://dx.doi.org/10.1053/j.seminoncol.2012.02.006
   PubMed Web of Science ®Google Scholar
• Bizama C, Garcia P, Espinoza JA, Weber H, Leal P, Nervi B, Roa JC. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev 2015; 41:222-234; PMID:25639632; http://dx.doi.org/10.1016/j.ctrv.2015.01.003
   PubMed Web of Science ®Google Scholar
• Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP. Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology 2006; 11:335-340; PMID:17607583; http://dx.doi.org/10.1080/10245330600915818
   PubMed Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM, Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907; PMID:20647400; http://dx.doi.org/10.1158/1055-9965.EPI-10-0437
   PubMed Web of Science ®Google Scholar
• Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007; 6:25; PMID:17407558; http://dx.doi.org/10.1186/1476-4598-6-25
   PubMed Web of Science ®Google Scholar
• Aznavoorian S, Stracke ML, Krutzsch H, Schiffmann E, Liotta LA. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells. J Cell Biol 1990; 110:1427-1438; PMID:2324200; http://dx.doi.org/10.1083/jcb.110.4.1427
   PubMed Web of Science ®Google Scholar
• Nelson D, Fisher S, Robinson B. The “Trojan Horse” approach to tumor immunotherapy: targeting the tumor microenvironment. J Immunol Res2014; 2014:789069; PMID:24955376
   PubMed Web of Science ®Google Scholar
• Ohtani H. Stromal reaction in cancer tissue: pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reactions. Pathol Int 1998; 48:1-9; PMID:9589457; http://dx.doi.org/10.1111/j.1440-1827.1998.tb03820.x
   PubMed Web of Science ®Google Scholar
• Tlsty TD. Stromal cells can contribute oncogenic signals. Semin Cancer Biol 2001; 11:97-104; PMID:11322829; http://dx.doi.org/10.1006/scbi.2000.0361
   PubMed Web of Science ®Google Scholar
• Tlsty TD. Searching for targets: the power of somatic cell genetics. Genome Res 2001; 11:187-188; PMID:11157780; http://dx.doi.org/10.1101/gr.177101
   PubMed Web of Science ®Google Scholar
• Tlsty TD, Hein PW. Know thy neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 2001; 11:54-59; PMID:11163151; http://dx.doi.org/10.1016/S0959-437X(00)00156-8
   PubMed Web of Science ®Google Scholar
• Croker A.K., Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008; 12:374-390; PMID:18182063; http://dx.doi.org/10.1111/j.1582-4934.2007.00211.x
   PubMed Web of Science ®Google Scholar
• Shicang Y, Guijun H, Guisheng Q, Yuying L, Guoming W, Ruiling G. Efficacy of chemotherapeutic agents under hypoxic conditions in pulmonary adenocarcinoma multidrug resistant cell line. J Chemother 2007; 19:203-211; PMID:17434831; http://dx.doi.org/10.1179/joc.2007.19.2.203
   PubMed Web of Science ®Google Scholar
• Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, Turbin D, Berquin IM, Mertens PR, Iftner T, Gilks CB, Dunn SE. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006; 66:4872-4879; PMID:16651443; http://dx.doi.org/10.1158/0008-5472.CAN-05-3561
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-257; PMID:11001068; http://dx.doi.org/10.1038/35025220
   PubMed Web of Science ®Google Scholar
• Pralhad T, Madhusudan S, Rajendrakumar K, Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 2003; 55:1045-1053; PMID:12956893; http://dx.doi.org/10.1211/0022357021819
   PubMed Web of Science ®Google Scholar
• Agrawal N, Bettegowda C, Cheong I, Geschwind JF, Drake CG, Hipkiss EL, Tatsumi M, Dang LH, Diaz LA, Jr, Pomper M, et al, Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004; 101:15172-15177; PMID:15471990; http://dx.doi.org/10.1073/pnas.0406242101
   PubMed Web of Science ®Google Scholar
• Bilton R, Trottier E, Pouyssegur J, Brahimi-Horn MC. ARDent about acetylation and deacetylation in hypoxia signalling. Trends Cell Biol2006; 16:616-621; PMID:17070052; http://dx.doi.org/10.1016/j.tcb.2006.10.002
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441:437-443; PMID:16724055; http://dx.doi.org/10.1038/nature04871
   PubMed Web of Science ®Google Scholar
• Pouyssegur J, Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem 2006; 387:1337-1346; PMID:17081104; http://dx.doi.org/10.1515/BC.2006.167
   PubMed Web of Science ®Google Scholar
• Melillo G. Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 2007; 26:341-352; PMID:17415529; http://dx.doi.org/10.1007/s10555-007-9059-x
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang D, Zhang S, Zhang W, Guo H, Zhao X. Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 2007; 249:188-197; PMID:16997457; http://dx.doi.org/10.1016/j.canlet.2006.08.016
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99:1441-1454; PMID:17895480; http://dx.doi.org/10.1093/jnci/djm135
   PubMed Web of Science ®Google Scholar
• Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3:453-458; PMID:12778135; http://dx.doi.org/10.1038/nrc1098
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Poste G. The “seed and soil” hypothesis revisited. Lancet Oncol 2008; 9:808; PMID:18672217; http://dx.doi.org/10.1016/S1470-2045(08)70201-8
   PubMed Web of Science ®Google Scholar
• Seretis F, Seretis C, Youssef H, Chapman M. Colorectal cancer: seed and soil hypothesis revisited. Anticancer Res 2014; 34:2087-2094; PMID:24778010
   PubMed Web of Science ®Google Scholar
• Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1038/nri1995
   PubMed Web of Science ®Google Scholar
• Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007; 7:139-147; PMID:17218951; http://dx.doi.org/10.1038/nrc2067
   PubMed Web of Science ®Google Scholar
• Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72:2473-2480.; PMID:22414581; http://dx.doi.org/10.1158/0008-5472.CAN-12-0122
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment, Nat. Immunol 2013; 14:1014-1022; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-949; PMID:15322536; http://dx.doi.org/10.1038/nm1093
   PubMed Web of Science ®Google Scholar
• Welters MJP, Kenter GG, van Steenwijk PJD, Lowik MJG, Berends-van der Meer DMA, Essahsah F, Stynenbosch LFM, Vloon APG, Ramwadhdoebe TH, Piersma SJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107:11895-11899; PMID:20547850; http://dx.doi.org/10.1073/pnas.1006500107
   PubMed Web of Science ®Google Scholar
• Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, et al. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol 2006; 177:1670-1678; PMID:16849476; http://dx.doi.org/10.4049/jimmunol.177.3.1670
   PubMed Web of Science ®Google Scholar
• Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, et al. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res 2003; 63:2535-2545; PMID:12750277
   PubMed Web of Science ®Google Scholar
• Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002; 196:541-549; PMID:12186845; http://dx.doi.org/10.1084/jem.20020732
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C. Dendritic cells as sensors of infection. Immunity 2001; 14:495-498; PMID:11371351; http://dx.doi.org/10.1016/S1074-7613(01)00136-4
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res 2005; 65:5020-5026; PMID:15958543; http://dx.doi.org/10.1158/0008-5472.CAN-04-4043
   PubMed Web of Science ®Google Scholar
• Long KB, Beatty GL, Harnessing the antitumor potential of macrophages for cancer immunotherapy Oncoimmunology 2013; 2:e26860; PMID:24498559; http://dx.doi.org/10.4161/onci.26860
   PubMedGoogle Scholar
• Fridlender ZG, Albelda SM. Modifying tumor-associated macrophages: An important adjunct to immunotherapy. Oncoimmunology 2013; 2:e26620; PMID:24498549; http://dx.doi.org/10.4161/onci.26620
   PubMedGoogle Scholar
• Amit M, Gil Z. Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase, Oncoimmunology 2013; 2:e27231; PMID:24498570; http://dx.doi.org/10.4161/onci.27231
   PubMed Web of Science ®Google Scholar
• Sahin M, Sahin E, Koksoy S. Regulatory T cells in cancer: an overview and perspectives on cyclooxygenase-2 and Foxp3 DNA methylation. Hum Immunol 2013; 74:1061-1068; PMID:23756166; http://dx.doi.org/10.1016/j.humimm.2013.05.009
   PubMed Web of Science ®Google Scholar
• O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C. Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223:114-131; PMID:18613832; http://dx.doi.org/10.1111/j.1600-065X.2008.00635.x
   PubMed Web of Science ®Google Scholar
• Chen S, Wang X, Wu X, Wei MQ, Zhang B, Liu X, Wang Y. IL-10 signalling blockade at the time of immunization inhibits Human papillomavirus 16 E7 transformed TC-1 tumour cells growth in mice. Cell Immunol 2014; 290:145-151; PMID:24983823; http://dx.doi.org/10.1016/j.cellimm.2014.06.002
   PubMed Web of Science ®Google Scholar
• Katz LH, Li Y, Chen JS, Munoz NM, Majumdar A, Chen J, Mishra L. Targeting TGF-b signaling in cancer. Expert Opin Ther Targets 2013; 17:743-760.; PMID:23651053; http://dx.doi.org/10.1517/14728222.2013.782287
   PubMed Web of Science ®Google Scholar
• Apetoh L, Vegran F, Ladoire S, Ghiringhelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr Mol Med 2011; 11:365-372; PMID:21568934; http://dx.doi.org/10.2174/156652411795976574
   PubMed Web of Science ®Google Scholar
• Alderton GK. Immunotherapy: Two hits are better than one. Nat Rev Immunol 2014; 14:431; PMID:24962259; http://dx.doi.org/10.1038/nri3710
   PubMed Web of Science ®Google Scholar
• Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Science Translational Medicine 2014; 6:237ra267; http://dx.doi.org/10.1126/scitranslmed.3007974
   Web of Science ®Google Scholar
• Wei MQ, Mengesha A, Good D, Anne J. Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 2008; 259:16-27; PMID:18063294; http://dx.doi.org/10.1016/j.canlet.2007.10.034
   PubMed Web of Science ®Google Scholar
• Kimura NT, Taniguchi S, Aoki K, Baba T. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 1980; 40:2061-2068; PMID:6989495
   PubMed Web of Science ®Google Scholar
• Cao S, Cripps A, Wei MQ. New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol 2010; 37:108-114; PMID:19671071; http://dx.doi.org/10.1111/j.1440-1681.2009.05268.x
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Dang LH, Abrams R, Huso DL, Dillehay L, Cheong I, Agrawal N, Borzillary S, McCaffery JM, Watson EL, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003; 100:15083-15088; PMID:14657371; http://dx.doi.org/10.1073/pnas.2036598100
   PubMed Web of Science ®Google Scholar
• Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001; 98:15155-15160; PMID:11724950; http://dx.doi.org/10.1073/pnas.251543698
   PubMed Web of Science ®Google Scholar
• Maletzki C, Gock M, Klier U, Klar E, Linnebacher M. Bacteriolytic therapy of experimental pancreatic carcinoma. World J Gastroenterol 2010; 16:3546-3552; PMID:20653063; http://dx.doi.org/10.3748/wjg.v16.i28.3546
   PubMed Web of Science ®Google Scholar
• Staedtke V, Bai RY, Sun W, Huang J, Kibler KK, Tyler BM, Gallia GL, Kinzler K, Vogelstein B, Zhou S, et al. Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget 2015; 6:5536-5546; PMID:25849940
   PubMed Web of Science ®Google Scholar
• Krick EL, Sorenmo KU, Rankin SC, Cheong I, Kobrin B, Thornton K, Kinzler KW, Vogelstein B, Zhou S, Diaz LA, Jr. Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res 2012; 73:112-118; PMID:22204296; http://dx.doi.org/10.2460/ajvr.73.1.112
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Science Translational Medicine 2014; 6:249ra111; PMID:25122639; http://dx.doi.org/10.1126/scitranslmed.3008982
   PubMed Web of Science ®Google Scholar
• Diaz LA, Jr, Cheong I, Foss CA, Zhang X, Peters BA, Agrawal N, Bettegowda C, Karim B, Liu G, Khan K, et al. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci 2005; 88:562-575; PMID:16162850; http://dx.doi.org/10.1093/toxsci/kfi316
   PubMed Web of Science ®Google Scholar
• Gelman AE, Turka LA. Autoimmunity heats up. Nat Med 2003; 9:1465-1466; PMID:14647523; http://dx.doi.org/10.1038/nm1203-1465
   PubMed Web of Science ®Google Scholar
• Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med 2001; 344:109-113; PMID:11150362; http://dx.doi.org/10.1056/NEJM200101113440206
   PubMed Web of Science ®Google Scholar
• Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344:30-37; PMID:11136958; http://dx.doi.org/10.1056/NEJM200101043440106
   PubMed Web of Science ®Google Scholar
• Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 2008; 14:1905-1912; PMID:18347194; http://dx.doi.org/10.1158/1078-0432.CCR-07-2050
   PubMed Web of Science ®Google Scholar
• Lee CH, Wu CL, Shiau AL. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 2008; 122:930-935; PMID:17960612; http://dx.doi.org/10.1002/ijc.23047
   PubMed Web of Science ®Google Scholar
• Lee CH, Hsieh JL, Wu CL, Hsu PY, Shiau AL. T cell augments the antitumor activity of tumor-targeting Salmonella. Appl Microbiol Biotechnol 2011; 90:1381-1388; PMID:21360146; http://dx.doi.org/10.1007/s00253-011-3180-z
   PubMed Web of Science ®Google Scholar
• Lee CH. Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. Appl Microbiol Biotechnol 2012; 93:517-523; PMID:22120621; http://dx.doi.org/10.1007/s00253-011-3695-3
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-998; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991
   PubMed Web of Science ®Google Scholar
• Ochsenbein AF. Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 2002; 9:1043-1055; PMID:12522443; http://dx.doi.org/10.1038/sj.cgt.7700540
   PubMed Web of Science ®Google Scholar
• Chen J, Liu XS. Development and function of IL-10 IFN-gamma-secreting CD4(+) T cells. J Leukoc Biol 2009; 86:1305-1310; PMID:19741156; http://dx.doi.org/10.1189/jlb.0609406
   PubMed Web of Science ®Google Scholar
• Jacobs JJ, Snackey C, Geldof AA, Characiejus D, Van Moorselaar RJ, Den Otter W. Inefficacy of therapeutic cancer vaccines and proposed improvements Casus of prostate cancer. Anticancer Res 2014; 34:2689-2700; PMID:24922629
   PubMed Web of Science ®Google Scholar
• Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011; 269:5-9; PMID:21477796; http://dx.doi.org/10.1016/j.cellimm.2011.03.003
   PubMed Web of Science ®Google Scholar
• Shouval DS, Ouahed J, Biswas A, Goettel JA, Horwitz BH, Klein C, Muise AM, Snapper SB. Interleukin 10 receptor signaling: master regulator of intestinal mucosal homeostasis in mice and humans. Adv Immunol 2014; 122:177-210; PMID:24507158; http://dx.doi.org/10.1016/B978-0-12-800267-4.00005-5
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-915; PMID:15340416; http://dx.doi.org/10.1038/nm1100
   PubMed Web of Science ®Google Scholar
• Liu XS, Dyer J, Leggatt GR, Fernando GJ, Zhong J, Thomas R, Frazer IH. Overcoming original antigenic sin to generate new CD8 T cell IFN-gamma responses in an antigen-experienced host. J Immunol 2006; 177:2873-2879; PMID:16920922; http://dx.doi.org/10.4049/jimmunol.177.5.2873
   PubMed Web of Science ®Google Scholar
• Liu XS, Xu Y, Hardy L, Khammanivong V, Zhao W, Fernando GJ, Leggatt GR, Frazer IH. IL-10 mediates suppression of the CD8 T cell IFN-gamma response to a novel viral epitope in a primed host. J Immunol 2003; 171:4765-4772; PMID:14568953; http://dx.doi.org/10.4049/jimmunol.171.9.4765
   PubMed Web of Science ®Google Scholar
• Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107:628-636; PMID:16179369; http://dx.doi.org/10.1182/blood-2005-07-2737
   PubMed Web of Science ®Google Scholar
• Chen J, Liu X. The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications Cell Immunol 2009; 254:85-90; PMID:19135891
   PubMed Web of Science ®Google Scholar
• Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, Wang Y, Wei MQ, Liu X. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol 2015; 293:126-129; PMID:25596475; http://dx.doi.org/10.1016/j.cellimm.2014.12.012
   PubMed Web of Science ®Google Scholar
• Berzofsky JA. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. Vaccine 2012; 30:4323-4327; PMID:22115635; http://dx.doi.org/10.1016/j.vaccine.2011.11.034
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765; PMID:11244051; http://dx.doi.org/10.1146/annurev.immunol.19.1.683
   PubMed Web of Science ®Google Scholar
• Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells, Nature Rev Immunol 2010; 10:170-181; http://dx.doi.org/10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• Kim JM, Brannan CI, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10  gene and chromosomal localization of the mouse and human genes. J Immunol 1992; 148:3618-3623; PMID:1350294
   PubMed Web of Science ®Google Scholar
• Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J, Spits H, Mosmann TR, Moore KW. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990; 250:830-832; PMID:2173142; http://dx.doi.org/10.1126/science.2173142
   PubMed Web of Science ®Google Scholar
• Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, deVries JE, Roncarolo MG, Mosmann TR, Moore KW. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci U S A 1991; 88:1172-1176; PMID:1847510; http://dx.doi.org/10.1073/pnas.88.4.1172
   PubMed Web of Science ®Google Scholar
• Rode HJ, Janssen W, Rosen-Wolff A, Bugert JJ, Thein P, Becker Y, Darai G. The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL10)-like gene. Virus Genes 1993; 7:111-116; PMID:8385838; http://dx.doi.org/10.1007/BF01702353
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Saccani S, Izotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc Natl Acad Sci U S A 2000; 97:1695-1700; PMID:10677520; http://dx.doi.org/10.1073/pnas.97.4.1695
   PubMed Web of Science ®Google Scholar
• Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 1997; 71:4857-4861; PMID:9151886
   PubMed Web of Science ®Google Scholar
• Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure 1995; 3:591-601.; PMID:8590020; http://dx.doi.org/10.1016/S0969-2126(01)00193-9
   PubMed Web of Science ®Google Scholar
• Zdanov A, Schalk-Hihi C, Menon S, Moore KW, Wlodawer A. Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J Mol Biol 1997; 268:460-467; PMID:9159483; http://dx.doi.org/10.1006/jmbi.1997.0990
   PubMed Web of Science ®Google Scholar
• Liu Y, Wei SH, Ho AS, de Waal Malefyt R, Moore KW. Expression cloning and characterization of a human IL-10 receptor. J Immunol 1994; 152:1821-1829; PMID:8120391
   PubMed Web of Science ®Google Scholar
• Tian XQ, Chen TC, Matsuoka LY, Wortsman J, Holick MF. Kinetic and thermodynamic studies of the conversion of previtamin D3 to vitamin D3 in human skin. J Biol Chem 1993; 268:14888-14892; PMID:8392061
   PubMed Web of Science ®Google Scholar
• Gabrysova L, Howes A, Saraiva M, O'Garra A. The regulation of IL-10 expression. Curr Top Microbiol Immunol 2014; 380:157-190; PMID:25004818
   PubMed Web of Science ®Google Scholar
• Howard M, O'Garra A. Biological properties of interleukin 10. Immunol Today 1992; 13:198-200; PMID:1385707; http://dx.doi.org/10.1016/0167-5699(92)90153-X
   PubMedGoogle Scholar
• Cardillo MR, Ippoliti F. Interleukin-6, interleukin-10 and heat shock protein-90 expression in renal epithelial neoplasias and surrounding normal-appearing renal parenchyma. Int J Immunopathol Pharmacol 2007; 20:37-46; PMID:17346426
   PubMed Web of Science ®Google Scholar
• Dummer W, Bastian BC, Ernst N, Schanzle C, Schwaaf A, Brocker EB. Interleukin-10 production in malignant melanoma: preferential detection of IL-10-secreting tumor cells in metastatic lesions. Int J Cancer 1996; 66:607-610; PMID:8647620; http://dx.doi.org/10.1002/(SICI)1097-0215(19960529)66:5<607::AID-IJC4>3.0.CO;2-X
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3:185-192; PMID:15180472; http://dx.doi.org/10.2174/1568010043343886
   PubMedGoogle Scholar
• Liu XS, Leerberg J, MacDonald K, Leggatt GR, Frazer I.H. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009; 183:51-58; PMID:19535638; http://dx.doi.org/10.4049/jimmunol.0802047
   PubMed Web of Science ®Google Scholar
• Ni G, Wang Y, Wu X, Wang X, Chen S, Liu X. Graphene oxide absorbed anti-IL10R antibodies enhance LPS induced immune responses in vitro and in vivo. Immunol. Lett 2012; 148:126-132; PMID:23064239; http://dx.doi.org/10.1016/j.imlet.2012.10.001
   PubMed Web of Science ®Google Scholar
• Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65:3437-3446; PMID:15833879
   PubMed Web of Science ®Google Scholar
• de Vos van Steenwijk PJ, Ramwadhdoebe TH, Lowik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 2012; 61:1485-1492; PMID:22684521; http://dx.doi.org/10.1007/s00262-012-1292-7
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008; 14:169-177; PMID:18172268; http://dx.doi.org/10.1158/1078-0432.CCR-07-1881
   PubMed Web of Science ®Google Scholar
• Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-1847; PMID:19890126; http://dx.doi.org/10.1056/NEJMoa0810097
   PubMed Web of Science ®Google Scholar
• Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med 1947; 66:461-467; PMID:18921791; http://dx.doi.org/10.3181/00379727-66-16124
   PubMed Web of Science ®Google Scholar
• Barbe S, Van Mellaert L, Theys J, Geukens N, Lammertyn E, Lambin P, Anne J. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 2005; 246:67-73; PMID:15869963; http://dx.doi.org/10.1016/j.femsle.2005.03.037
   PubMed Web of Science ®Google Scholar